Skip to content

Downstream Molecular Signals of P2Y12 Receptors in Hyporeactive Patients Under Clopidogrel Treatment A Possible Mechanism of HOTPR(High On-Treatment Platelet Reactivity)

Downstream Molecular Signals of P2Y12 Receptors in Hyporeactive Patients Under Clopidogrel Treatment (A Possible Mechanism of HOTPR:High On- Treatment Platelet Reactivity)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03190005
Enrollment
35
Registered
2017-06-16
Start date
2017-01-01
Completion date
2017-11-01
Last updated
2019-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stable Angina

Keywords

PRU, P2Y12 receptor

Brief summary

The investigators designed the following experiment to observe the pattern of administration in vitro, which can be completely excluded liver enzyme cytochrome P450 metabolism under the influence and observe the relevant P2Y12 receptor downstream signal changes, hope in the above experiments, that the human body directly for the difference between the existence of drug reactions exist.

Detailed description

Platelet reactivity has been accepted as an indicator of the reaction of the P2Y12 inhibitor during treatment, currently, the existing evidence to support the post-treatment platelet activity can be used to distinguish the potential risk among patients who received percutaneous transluminal coronary angioplasty after ischemic / thrombotic events. The risks of stent thrombosis, of which, by analysis of the PRU (P2Y12 reaction units) value level of VerifyNow System has been considered an international standard tools. PRU value by VerifyNow system can easily and quickly showed platelet reactivity relative to short or long term risk stratification under dual antiplatelet agents(aspirin and clopidogrel) after stents implantation. High PRU response units (drug poor responders) in accordance with the 2013 publication of the European Society of Cardiology guidelines defined of platelet function, is PRU not less than 208(≥208). The investigators ran a previous related plan within 2014 under the medical study project budget of the Taipei City hospital, which named platelet reactivity as a post-percutaneous coronary stent implantation antiplatelet adjust the reference, it has been figured that responsibility under the P2Y12 receptor inhibitors were significantly different between the taiwanese and Caucasians (taiwanese revealed clopidogrel lower responsive, but stronger reaction to ticagrelor), although low response to clopidogrel between taiwanese (In fact, according to our experiments, 30 days after medication, the rate of HOTPR-High On- Treatment Platelet Reactivity; namely PRU≥208, the taiwanese and Caucasians are very close to each), but it has relative lower subacute stent thrombosis rate than the Caucasian at 30 days(This reaction is also known as the Asian paradox ), according to literature known abroad because of the high prevalence of CYP2C19 point gene deletion rate among the Asians (compare with Caucasians: \ 65% vs \ 30%); there also suggested other possible explanations: Caucasian factor V Leiden (G1691A) and prothrombin (G20210A) a higher proportion of mutations, on hemostatic factors (fibrinogen, d-dimer, and factor VIII) and plasma endothelial activation markers (such as von Willebrand factor, intercellular adhesion molecule 1, and E-selectin) existed differences between the races; in addition, a number of different indicators of inflammation, such as CRP. Asians show lower level CRP than the Caucasians. However, did the investigators found the true answer? So, the investigators designed the following experiment, through the mode of drug administration in vitro, can completely exclude the influence of the liver metabolic enzyme cytochrome P450, and observe the relevant downstream signals of P2Y12 receptors. The investigators believed through the current study, the internal differences in drug responsibility can be clarified.

Interventions

DRUGclopidogrel

routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)

DRUGPlacebos

no medication, healthy subjects.

Sponsors

Taipei City Hospital
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* DAPT(Dual antiplatelet therapy) after regular stent implantation.

Exclusion criteria

* allergy to DAPT(Dual antiplatelet therapy). major bleeding intolerance to DAPT(Dual antiplatelet therapy).

Design outcomes

Primary

MeasureTime frameDescription
PRU(Platelet Rreactivity Unit) 24 Hours After DAPT(Dual AntiPlatelet Therapy) Western Blot After Medication24 hoursPRU(Platelet Rreactivity Unit) 24 hours after DAPT(Dual AntiPlatelet Therapy) Western blot after medication

Countries

Taiwan

Participant flow

Participants by arm

ArmCount
Group 1
placebo control without medication. Placebos: no medication, healthy subjects.
5
Group 1
placebo control without medication. Placebos: no medication, healthy subjects.
5
Group 2
hyper-reactive responser after clopidogrel. clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)
5
Group 2
hyper-reactive responser after clopidogrel. clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)
5
Group 3
hypo-reactive responser after clopidogrel. clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)
5
Group 3
hypo-reactive responser after clopidogrel. clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)
5
Group 4
normo-reactive responser after clopidogrel. clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)
5
Group 4
normo-reactive responser after clopidogrel. clopidogrel: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)
5
Group 5
reaction after OPC-13013
5
Group 5
reaction after OPC-13013
5
Group 6
reaction after AR-C
5
Group 6
reaction after AR-C
5
Group 7
reaction after simastatin
5
Group 7
reaction after simastatin
5
Total70

Baseline characteristics

CharacteristicGroup 2Group 3Group 4Group 5Group 6Group 7Group 1Total
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
1 Participants2 Participants3 Participants3 Participants2 Participants2 Participants2 Participants15 Participants
Age, Categorical
Between 18 and 65 years
4 Participants3 Participants2 Participants2 Participants3 Participants3 Participants3 Participants20 Participants
Age, Continuous64.92 years
STANDARD_DEVIATION 13.24
66.89 years
STANDARD_DEVIATION 10.72
63.35 years
STANDARD_DEVIATION 13.62
65.09 years
STANDARD_DEVIATION 11.13
61.23 years
STANDARD_DEVIATION 10.34
68.32 years
STANDARD_DEVIATION 15.12
62.52 years
STANDARD_DEVIATION 11.12
67.36 years
STANDARD_DEVIATION 13.82
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
5 Participants5 Participants5 Participants5 Participants5 Participants5 Participants5 Participants35 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Region of Enrollment
Taiwan
5 participants5 participants5 participants5 participants5 participants5 participants5 participants5 participants
Sex: Female, Male
Female
3 Participants1 Participants2 Participants2 Participants1 Participants2 Participants2 Participants13 Participants
Sex: Female, Male
Male
2 Participants4 Participants3 Participants3 Participants4 Participants3 Participants3 Participants22 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
EG006
affected / at risk
deaths
Total, all-cause mortality
0 / 50 / 50 / 50 / 50 / 50 / 50 / 5
other
Total, other adverse events
0 / 50 / 50 / 50 / 50 / 50 / 50 / 5
serious
Total, serious adverse events
0 / 50 / 50 / 50 / 50 / 50 / 50 / 5

Outcome results

Primary

PRU(Platelet Rreactivity Unit) 24 Hours After DAPT(Dual AntiPlatelet Therapy) Western Blot After Medication

PRU(Platelet Rreactivity Unit) 24 hours after DAPT(Dual AntiPlatelet Therapy) Western blot after medication

Time frame: 24 hours

Population: PRU(Platelet Rreactivity Unit) 24 hours after DAPT(Dual AntiPlatelet Therapy) Western blot after medication

ArmMeasureValue (MEAN)Dispersion
Group 1PRU(Platelet Rreactivity Unit) 24 Hours After DAPT(Dual AntiPlatelet Therapy) Western Blot After Medication148 PRU(Platelet Rreactivity Unit)Standard Deviation 3
Group 2PRU(Platelet Rreactivity Unit) 24 Hours After DAPT(Dual AntiPlatelet Therapy) Western Blot After Medication289 PRU(Platelet Rreactivity Unit)Standard Deviation 4
Group 3PRU(Platelet Rreactivity Unit) 24 Hours After DAPT(Dual AntiPlatelet Therapy) Western Blot After Medication79 PRU(Platelet Rreactivity Unit)Standard Deviation 1
Group 4PRU(Platelet Rreactivity Unit) 24 Hours After DAPT(Dual AntiPlatelet Therapy) Western Blot After Medication132 PRU(Platelet Rreactivity Unit)Standard Deviation 6
Group 5PRU(Platelet Rreactivity Unit) 24 Hours After DAPT(Dual AntiPlatelet Therapy) Western Blot After Medication81 PRU(Platelet Rreactivity Unit)Standard Deviation 3
Group 6PRU(Platelet Rreactivity Unit) 24 Hours After DAPT(Dual AntiPlatelet Therapy) Western Blot After Medication62 PRU(Platelet Rreactivity Unit)Standard Deviation 2
Group 7PRU(Platelet Rreactivity Unit) 24 Hours After DAPT(Dual AntiPlatelet Therapy) Western Blot After Medication114 PRU(Platelet Rreactivity Unit)Standard Deviation 9

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026